Indian pharmaceutical and healthcare firms are set for a significant fundraising push, aiming to garner ₹12,000-13,000 crore through IPOs in the coming months. Approximately fifteen companies are expected to enter the primary market, with fertility and women’s health segments particularly in focus.
Ind-Ra downgrades Jana Capital, Jana Holdings NCDs to default
India Ratings downgraded Jana Capital and Jana Holdings’ NCDs to default after both entities extended debt repayments by six months due to refinancing challenges. Jana